Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Adalimumab for AMD Non-responders
NCT01136252Phase 2Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- May 2010
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in choroidal neovascularization (CNV), sponsored by Vall d'Hebron Research Institute. Started May 2010; status: completed.
02
Drugs
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01136252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01136252.